

- | | |
|--|---|
| <p>The Deliberate Misdiagnosis of Major Depression in Primary Care 333
Kathryn Rost, PhD; G. Richard Smith, MD; Daryl B. Matthews, MD, PhD; Ben Guise, MD</p> <p>Physicians and Smoking Cessation: A Survey of Office Procedures and Practices in the Community Intervention Trial for Smoking Cessation 341
Elizabeth A. Lindsay, PhD; Judith K. Ockene, PhD; Norman Hymowitz, PhD; Carol Giffen, DVM; Larry Berger, MD; Paul Pomrehn, MD; for the Community Intervention Trial for Smoking Cessation Research Group</p> <p>Predicting Work Status for Patients in an Occupational Medicine Setting Who Report Back Pain 349
Marie A. Krousel-Wood, MD, MSPH; Todd W. McCune, MD, MPH; Ahmed Abdo, PhD; Richard N. Re, MD</p> <p>Clinical Risk Factors for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteriuria in a Skilled-Care Nursing Home 357
Patrick P. Coll, MB, BCh; Benjamin F. Crabtree, PhD; Patrick J. O'Connor, MD, MPH; Scott Klenzak</p> | <p>Primary Prevention of Coronary Heart Disease in Women: Should Asymptomatic Women 50 Years of Age Take Aspirin Regularly? 361
Scott E. Woods, MD</p> <hr/> <p style="text-align: center;"><i>Brief Reports</i></p> <p>Accurate Dosing of Pediatric Medications 365
Ronald D. Reynolds, MD</p> <p>The Family Physician and Industrial Hygiene 372
John R. Wheat, MD, MPH; Jerry T. McKnight, MD; William H. Weems, DrPH</p> <hr/> <p style="text-align: center;"><i>Departments</i></p> <p>Family Album 305</p> <p>Software Review 311</p> <p>Book Reviews 312</p> <p>Audiovisual Review 314</p> <p>Instructions for Authors 377</p> <p>Classified Advertising 383</p> <p>Index to Advertisers Cover 3</p> |
|--|---|

ARCHIVES

OF

FAMILY MEDICINE

Editor:

Marjorie A. Bowman, MD, MPA
Bowman Gray School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157-1084
Phone: (910) 716-7318
Fax: (910) 716-5850

Deputy Editor:

Joseph C. Konen, MD, MSPH
Winston-Salem, NC

Assistant to Editor:

Tina M. Gibson

Associate Editors:

Louise S. Acheson, MD, MS
Cleveland, Ohio

Charles E. Driscoll, MD
Iowa City, Iowa

Steven C. Zweig, MD, MSPH
Columbia, Mo

Editorial Board:

W. Eugene Broadhead, MD, PhD
Durham, NC

Allen J. Dietrich, MD
Hanover, NH

John G. Halvorsen, MD, MS
Minneapolis, Minn

Myron S. Magen, DO
E. Lansing, Mich

Patrick J. O'Connor, MD, MPH
St Paul, Minn

Barbara D. Reed, MD, MSPH
Ann Arbor, Mich

Milton H. Seifert, MD
Excelsior, Minn

Thomas L. Speros, MD
Washington, NC

David H. Thom, MD, MPH, PhD
Palo Alto, Calif

Series Editors:**Practice Management:**

Christian N. Ramsey, Jr, MD
Oklahoma City, Okla

Ethics:

Katherine C. Krause, MD
Hartford, Conn

Prevention and Health Promotion:

Robert C. Rinaldi, PhD
Chicago, Ill

Science and Technology:

Jerod M. Loeb, PhD
Chicago, Ill

Statistical Consultant:

Mark A. Espeland, PhD
Winston-Salem, NC


Book and Software Review:

Michael L. Adler, MD
Winston-Salem, NC

DDAVP[®] Nasal Spray

(desmopressin acetate) 5mL

Dry Nights For Good Mornings



Brief Summary

CONTRADICTION: Known hypersensitivity to DDAVP Nasal Spray

WARNINGS:

1. For intranasal use only
2. In very young and elderly patients in particular, fluid intake should be adjusted in order to decrease the potential occurrence of water intoxication and hyponatremia. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality and resulting seizures.

PRECAUTIONS:

General: DDAVP Nasal Spray at high dosage has infrequently produced a slight elevation of blood pressure, which disappeared with a reduction in dosage. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease because of possible rise in blood pressure.

DDAVP Nasal Spray should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, because these patients are prone to hyponatremia.

Central Cranial Diabetes Insipidus: Since DDAVP Nasal Spray is used intranasally, changes in the nasal mucosa such as scarring, edema, or other disease may cause erratic, unreliable absorption in which case DDAVP Nasal Spray should not be used. For such situations, DDAVP injection should be considered.

Primary Nocturnal Enuresis: If changes in the nasal mucosa have occurred, unreliable absorption may result. DDAVP Nasal Spray should be discontinued until the nasal problems resolve.

Information for Patients: Patients should be informed that the bottle accurately delivers 50 doses of 10 mcg each. Any solution remaining after 50 doses should be discarded since the amount delivered thereafter may be substantially less than 10 mcg of drug. No attempt should be made to transfer remaining solution to another bottle. Patients should be instructed to read accompanying directions on use of the spray pump carefully before use.

Laboratory Tests: Laboratory tests for following the patient with central cranial diabetes insipidus or post-surgical or head trauma-related polyuria and polydipsia include urine volume and osmolality. In some cases plasma osmolality may be required. For the healthy patient with primary nocturnal enuresis, serum electrolytes should be checked at least once if therapy is continued beyond 7 days.

Drug Interactions: Although the pressor activity of DDAVP Nasal Spray is very low compared to the antidiuretic activity, use of large doses of DDAVP Nasal Spray with other pressor agents should only be done with careful patient monitoring.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Teratology studies in rats have shown no abnormalities. No further information is available.

Pregnancy-Category B: Reproduction studies performed in rats and rabbits with doses up to 12.5 times the human intranasal dose (i.e. about 125 times the total adult human dose given systemically) have revealed no evidence of harm to the fetus due to desmopressin acetate. There are several publications of management of diabetes insipidus in pregnant women with no harm to the fetus reported; however, no controlled studies in pregnant women have been carried out. Published reports stress that, as opposed to preparations containing the natural hormones, DDAVP Nasal Spray (desmopressin acetate) in antidiuretic doses has no uterotropic action, but the physician will have to weigh possible therapeutic advantages against possible dangers in each individual case.

Nursing Mothers: There have been no controlled studies in nursing mothers. A single study in a post-partum woman demonstrated a marked change in breast milk, but little if any change in assayed DDAVP Nasal Spray in breast milk following an intranasal dose of 10 mcg.

Pediatric Use: Primary Nocturnal Enuresis: DDAVP Nasal Spray has been used in childhood nocturnal enuresis. Short-term (4-8 weeks) DDAVP Nasal Spray administration has been shown to be safe and modestly effective in children aged 6 years or older with severe childhood nocturnal enuresis. Adequately controlled studies with DDAVP Nasal Spray in primary nocturnal enuresis have not been conducted beyond 4-8 weeks. The dose should be individually adjusted to achieve the best results.

Central Cranial Diabetes Insipidus: DDAVP Nasal Spray has been used in children with diabetes insipidus. Use in infants and children will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. The dose must be individually adjusted to the patient with attention in the very young to the danger of an extreme decrease in plasma osmolality with resulting convulsions. Dose should start at 0.05 mL or less.

Since the spray cannot deliver less than 0.1 mL (10 mcg), smaller doses should be administered using the rhinal tube delivery system. Do not use the nasal spray in pediatric patients requiring less than 0.1 mL (10 mcg) per dose.

There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to local inactivation of the peptide.

ADVERSE REACTIONS: Infrequently, high dosages have produced transient headache and nausea. Nasal congestion, rhinitis and flushing have also been reported occasionally along with mild abdominal cramps. These symptoms disappeared with reduction in dosage. Nose-bleed, sore throat, cough and upper respiratory infections have also been reported.

The following table lists the percent of patients having adverse experiences without regard to relationship to study drug from the pooled pivotal study data for nocturnal enuresis.

ADVERSE REACTION	PLACEBO	DDAVP	DDAVP
	(N=59)	20 mcg	40 mcg
	%	(N=60)	(N=61)
BODY AS A WHOLE			
Abdominal Pain	0	2	2
Asthenia	0	0	2
Chills	0	0	5
Headache	0	2	5
Throat Pain	2	0	0
NERVOUS SYSTEM			
Depression	2	0	0
Dizziness	0	0	3
RESPIRATORY SYSTEM			
Epistaxis	2	3	0
Nasal Pain	0	2	0
Respiratory Infection	2	0	0
Rhinitis	2	8	3
CARDIOVASCULAR SYSTEM			
Vasodilation	2	0	0
DIGESTIVE SYSTEM			
Gastrointestinal Disorder	0	2	0
Nausea	0	0	2
SKIN & APPENDAGES			
Leg Rash	2	0	0
Rash	2	0	0
SPECIAL SENSES			
Conjunctivitis	0	2	0
Edema Eyes	0	2	0
Lachrymation Disorder	0	0	2

OVERDOSAGE: See adverse reactions above. In case of overdosage, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for DDAVP Nasal Spray. An oral LD₅₀ has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.

HOW SUPPLIED: A 5-mL bottle with spray pump delivering 50 doses of 10 mcg (NDC 0075-2450-02). Also available as 2.5 mL per vial, packaged with two rhinal tube applicators per carton (NDC 0075-2450-01). Keep refrigerated at 2°-8°C (36°-46°F). When traveling, product will maintain stability for up to 3 weeks when stored at room temperature, 22°C (72°F).

CAUTION: Federal (U.S.A.) law prohibits dispensing without prescription.

Please see full prescribing information in product circular.

References:

1. Aladjem M, Wohl R, Boichis H, et al: Desmopressin in nocturnal enuresis. *Arch Dis Child* 1982;57:137-140.
2. Bloom DA: The American experience with desmopressin. *Clin Pediatr* 1993(July, special edition):28-31.

Manufactured by
RHÔNE-POULENC RORER
RHÔNE-POULENC RORER PHARMACEUTICALS INC.
500 ARCOLA ROAD
COLLECÉVILLE, PA 19426
By Ferring Pharmaceuticals, Malmö, Sweden

ARCHIVES

OF

FAMILY MEDICINE

Publication Staff

Offices: 515 N State St
Chicago, IL 60610

Editorial Processing Department, Specialty Journals

Director: Paula Glitman

Manager: Barbara Clark

Freelance Manager:
Vickey Golden

Assistant Freelance Coordinator:

Richard T. Porter

Senior Copy Editor/Atex Specialist:

Paul Frank

Senior Copy Editor:

Janice Snyder

Copy Editors:

Diane L. Cannon

Gwen Chaffen

Mary E. Coerver

Vonda L. Meltesen

Manuscript Records Clerk:

Tonja Glover

Electronic Publishing Department

Director: Mary C. Steermann

Assistant Director: Jaye Matthews

Manager, Color:

Thomas J. Handrigan

Graphics & Color Coordinator:

JoAnne Weiskopf

Electronic Coordinator:

Mary Ellen Johnston

Graphic Designer:

Charl Richey-Davis

Electronic Production Associate:

Linda Knott

Electronic Production Operators:

Gail Barrett

Brenda Chandler-Haynes

Leslie Koch

Mary Ann Kuranda

Peter Watkins

Graphics Operators:

Carolyn Luton

Regina Vander Reyden

Manager, Proofreading:

Teresa H. Omietek

Proofreaders:

Kathleen Czernik

Brenda J. Gregoline

Daniel James

Production Assistant: Janey Stennis

Production & Distribution Department

Director: Carl Braun

Manager: Carole Piszker

Production Associates:

Debbie Pogorzelski

Christine M. Wagenknecht

E. Ruth White

Senior Production Assistant:

Kira Culver

Production Assistant:

Jo Anne Turner

Manager, Distribution:

Paul Gasecki

Publishing Operations Division Office

Manager, Budgets & Costs:

Bonnie Van Cleven

Manager, Advertising Production:

Vanessa Hayden

Staff Assistant: Diane Darnell

Office Manager: Karen Branham

Production Assistant:

Valerie Balkcom

Circulation Department

Director: Beverly Martin

Reprints: Rita Houston

Specialty Journal Division Office

Administrative Assistant:

Marla Hall

Licensing & Indexing Department

Director: Norman Frankel

Staff:

George Kruto

Mary Kay Tinerella

Permissions: Laslo Hunyady

